You are here

CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

Submitted by admin on April 11, 2018 - 11:57pm

Source:

CP Wire

News Tags:

clinical trials

Headline:

CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

snippet:

Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatment

Results support plans for advancing to Phase 3 in the second half of 2018